The pathogenesis of idiopathic pulmonary fibrosis (IPF) involves a complex interplay of cell
types and signaling pathways. Recurrent alveolar epithelial cell (AEC) injury may occur in …

Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide,
reducing their quality of life and leading to death from respiratory failure within years of …

Fibrosis is a pathological feature of most chronic inflammatory diseases. Fibrosis, or
scarring, is defined by the accumulation of excess extracellular matrix components. If highly …

This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

The contribution of the immune system to idiopathic pulmonary fibrosis (IPF) remains poorly
understood. While most sources agree that IPF does not result from a primary …

Pulmonary fibrosis is a highly heterogeneous and lethal pathological process with limited
therapeutic options. Although research on the pathogenesis of pulmonary fibrosis has …

Rationale: Idiopathic pulmonary fibrosis (IPF) has an unknown etiology and poor prognosis.
Several large-scale epidemiologic studies have been conducted predominantly in Western …

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some …

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis, represents a chronic and
progressive disease with high mortality and limited therapeutic options. Excessive …

Myofibroblasts accumulate in the spaces between organ structures and produce
extracellular matrix (ECM) proteins, including collagen I. They are the primary “effector” cells …